{"id":3037,"date":"2016-11-21T16:00:00","date_gmt":"2016-11-21T16:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/"},"modified":"2016-11-21T16:00:00","modified_gmt":"2016-11-21T16:00:00","slug":"xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/","title":{"rendered":"XVIVO Perfusion har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq Stockholm och offentligg\u00f6r prospekt"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>Nasdaq Stockholms bolagskommitt\u00e9 har godk\u00e4nt XVIVO Perfusion AB (\u201dXVIVO Perfusion\u201d) f\u00f6r upptagande till handel p\u00e5 huvudlistan p\u00e5 sedvanliga villkor.<\/strong><\/div>\n<p><span>F\u00f6rsta dag f\u00f6r handel i XVIVO Perfusions aktier p\u00e5 Nasdaq Stockholm \u00e4r planerad till m\u00e5ndagen den 28 november 2016. Genom noteringen upph\u00f6r XVIVO Perfusions notering p\u00e5 Nasdaq First North Premier. Sista dag f\u00f6r handel p\u00e5 Nasdaq First North Premier \u00e4r planerad till fredagen den 25 november 2016. <\/span><\/p>\n<p><span>XVIVO Perfusions aktier kommer att handlas under samma kortnamn som tidigare, dvs. \u201dXVIVO\u201d. Aktien beh\u00e5ller \u00e4ven samma ISIN-kod som tidigare, dvs. SE0004840718. Det sker inte n\u00e5got utgivande av nya aktier i samband med listbytet och aktie\u00e4gare i XVIVO Perfusion beh\u00f6ver inte vidta n\u00e5gra \u00e5tg\u00e4rder med anledning av detta.<\/span><\/p>\n<p><span>F\u00f6r ytterligare information h\u00e4nvisas till det prospekt som har uppr\u00e4ttats med anledning av listbytet och som har godk\u00e4nts av Finansinspektionen. Prospektet finns bland annat tillg\u00e4ngligt p\u00e5 XVIVO Perfusions webbplats www.xvivoperfusion.com\/corporate.<\/span><\/p>\n<p><span>Gernandt &amp; Danielsson \u00e4r legal r\u00e5dgivare i samband med noteringen.<\/span><\/p>\n<p><span>G\u00f6teborg 21 november 2016<br \/> Magnus Nilsson, VD<br \/>XVIVO Perfusion AB (publ)<\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, tel: +1\u00a0720\u00a0616 2101, e-post: christoffer.rosenblad@xvivoperfusion.com<br \/>Magnus Nilsson, VD, tel: 031-788 21 50, e-post: magnus.nilsson@xvivoperfusion.com<\/span><\/p>\n<p><span>F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/span><\/p>\n<p><span>Informationen i detta pressmeddelande l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande klockan 17:00 den 21 november 2016.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nasdaq Stockholms bolagskommitt\u00e9 har godk\u00e4nt XVIVO Perfusion AB (\u201dXVIVO Perfusion\u201d) f\u00f6r upptagande till handel p\u00e5 huvudlistan p\u00e5 sedvanliga villkor. F\u00f6rsta&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3037","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-ci"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XVIVO Perfusion har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq Stockholm och offentligg\u00f6r prospekt - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq Stockholm och offentligg\u00f6r prospekt - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Nasdaq Stockholms bolagskommitt\u00e9 har godk\u00e4nt XVIVO Perfusion AB (\u201dXVIVO Perfusion\u201d) f\u00f6r upptagande till handel p\u00e5 huvudlistan p\u00e5 sedvanliga villkor. F\u00f6rsta...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\\\/\",\"name\":\"XVIVO Perfusion har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq Stockholm och offentligg\u00f6r prospekt - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2016-11-21T16:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq Stockholm och offentligg\u00f6r prospekt\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq Stockholm och offentligg\u00f6r prospekt - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq Stockholm och offentligg\u00f6r prospekt - XVIVO","og_description":"Nasdaq Stockholms bolagskommitt\u00e9 har godk\u00e4nt XVIVO Perfusion AB (\u201dXVIVO Perfusion\u201d) f\u00f6r upptagande till handel p\u00e5 huvudlistan p\u00e5 sedvanliga villkor. F\u00f6rsta...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/","name":"XVIVO Perfusion har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq Stockholm och offentligg\u00f6r prospekt - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2016-11-21T16:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-har-godkants-for-notering-pa-nasdaq-stockholm-och-offentliggor-prospekt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion har godk\u00e4nts f\u00f6r notering p\u00e5 Nasdaq Stockholm och offentligg\u00f6r prospekt"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3037","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3037"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}